Q3 EPS Forecast for Coya Therapeutics Boosted by Analyst

Key Points

• HC Wainwright has significantly raised their Q3 2025 earnings per share estimate for Coya Therapeutics to $0.02, up from a prior forecast of ($0.24).
• The firm maintains a "Buy" rating on Coya Therapeutics with a price target of $18.00, while consensus earnings estimate for the full year remains at ($1.15) per share.
• Coya Therapeutics' stock has experienced a 3.5% increase, opening at $6.73, with a market capitalization of $112.56 million.

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 earnings estimates for Coya Therapeutics in a report released on Monday, August 25th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.02 for the quarter, up from their previous estimate of ($0.24). HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics' FY2025 earnings at ($1.30) EPS.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.78 million.

Several other brokerages also recently issued reports on COYA. D. Boral Capital reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, August 25th. Wall Street Zen downgraded shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Lake Street Capital initiated coverage on shares of Coya Therapeutics in a research report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price objective for the company. Finally, Chardan Capital reissued a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $16.50.

Coya Therapeutics Trading Down 2.2%

NASDAQ:COYA traded down $0.15 during trading hours on Wednesday, hitting $6.56. The stock had a trading volume of 38,718 shares, compared to its average volume of 68,898. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $10.24. The business has a 50 day simple moving average of $6.15 and a two-hundred day simple moving average of $6.08. The company has a market cap of $109.75 million, a PE ratio of -5.29 and a beta of 0.26.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds have recently added to or reduced their stakes in COYA. Geode Capital Management LLC boosted its holdings in Coya Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock worth $863,000 after purchasing an additional 8,267 shares during the period. XTX Topco Ltd acquired a new position in Coya Therapeutics in the fourth quarter worth $59,000. Tower Research Capital LLC TRC boosted its holdings in Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after purchasing an additional 4,777 shares during the period. Northern Trust Corp boosted its holdings in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the period. Finally, Jane Street Group LLC acquired a new position in Coya Therapeutics in the fourth quarter worth $74,000. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.